URL has been copied successfully!
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Barclays analyst Glen Santangelo upgraded Phathom Pharmaceuticals Inc (NASDAQ:PHAT) from Equal-Weight to Overweight and raised the price target from $16 to $18. Phathom Pharmaceuticals shares closed at $10.79 on Thursday. See how other analysts view this stock.
- BMO Capital analyst Ameet Thakkar …
Please follow us:
This post was originally published here
